DE69521789T2 - Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten - Google Patents

Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten

Info

Publication number
DE69521789T2
DE69521789T2 DE69521789T DE69521789T DE69521789T2 DE 69521789 T2 DE69521789 T2 DE 69521789T2 DE 69521789 T DE69521789 T DE 69521789T DE 69521789 T DE69521789 T DE 69521789T DE 69521789 T2 DE69521789 T2 DE 69521789T2
Authority
DE
Germany
Prior art keywords
nonantibody
fusion protein
domain
growth factor
antibody parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69521789T
Other languages
English (en)
Other versions
DE69521789D1 (de
Inventor
J Larochelle
A Aaronson
Olaf Dirsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69521789D1 publication Critical patent/DE69521789D1/de
Application granted granted Critical
Publication of DE69521789T2 publication Critical patent/DE69521789T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69521789T 1994-02-01 1995-02-01 Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten Expired - Fee Related DE69521789T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18955294A 1994-02-01 1994-02-01
PCT/US1995/000974 WO1995021258A1 (en) 1994-02-01 1995-02-01 Fusion proteins that include antibody and nonantibody portions

Publications (2)

Publication Number Publication Date
DE69521789D1 DE69521789D1 (de) 2001-08-23
DE69521789T2 true DE69521789T2 (de) 2002-04-25

Family

ID=22697828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521789T Expired - Fee Related DE69521789T2 (de) 1994-02-01 1995-02-01 Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten

Country Status (8)

Country Link
US (1) US6403769B1 (de)
EP (1) EP0742830B1 (de)
JP (1) JPH09509054A (de)
AT (1) ATE203274T1 (de)
AU (1) AU689214B2 (de)
CA (1) CA2182498A1 (de)
DE (1) DE69521789T2 (de)
WO (1) WO1995021258A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
FR2746815A1 (fr) * 1996-03-26 1997-10-03 Pasteur Institut Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6887475B1 (en) 1996-11-07 2005-05-03 Lorantis Limited Notch
PL333302A1 (en) * 1996-11-07 1999-11-22 Lorantis Ltd Notch proteine
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
CA2380331C (en) 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
DK1407017T3 (en) 2000-11-07 2009-09-21 Zymogenetics Inc Human receptor for tumor nekrose faktor
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
PT2301965E (pt) 2002-10-16 2015-05-20 Purdue Pharma Lp Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização
WO2004085476A2 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EP1856156A2 (de) 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen
ES2772674T3 (es) 2005-05-12 2020-07-08 Zymogenetics Inc Composiciones y métodos para modular respuestas inmunitarias
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
KR101700711B1 (ko) 2007-11-21 2017-01-31 로스킬드 유니베르시테트 얼음-결합 활성을 포함하는 폴리펩티드
US8653020B2 (en) 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
NZ588671A (en) * 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP6324970B2 (ja) 2012-09-27 2018-05-23 バイオケア メディカル， エルエルシー 抗ウロプラキンｉｉ抗体システムおよび方法
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
EP2964260A2 (de) 2013-03-06 2016-01-13 F. Hoffmann-La Roche AG Verfahren zur behandlung und prävention einer antikrebsmittelresistenz
EP2968498A4 (de) 2013-03-15 2016-09-07 Biogen Ma Inc Faktor-ix-polypeptidformulierungen
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
DK3052522T3 (da) 2013-10-03 2020-02-24 Biocare Medical Llc Anti-sox 10 antistofsystemer og -fremgangsmåder
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2019152827A1 (en) * 2018-02-02 2019-08-08 AskGene Pharma, Inc. Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1991005856A1 (en) 1989-10-13 1991-05-02 Loyola University Of Chicago Chimeric monoclonal antibodies generated by trans-splicing
JPH09506761A (ja) 1990-11-09 1997-07-08 ステファン ディー．ギリーズ サイトカインの免疫複合体

Also Published As

Publication number Publication date
US6403769B1 (en) 2002-06-11
CA2182498A1 (en) 1995-08-10
WO1995021258A1 (en) 1995-08-10
EP0742830B1 (de) 2001-07-18
JPH09509054A (ja) 1997-09-16
DE69521789D1 (de) 2001-08-23
AU689214B2 (en) 1998-03-26
EP0742830A1 (de) 1996-11-20
ATE203274T1 (de) 2001-08-15
AU1690295A (en) 1995-08-21

Similar Documents

Publication Publication Date Title
DE69521789D1 (de) Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
Kurucz et al. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies
KR950700419A (ko) 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)
CA2312188A1 (en) Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
AR052374A2 (es) Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunologlubina y anticuerpo agonista monoclonal que se lig
IL100343A0 (en) G protein coupled glutamate receptors
DE3382495D1 (de) Protein-a material und dessen herstellung.
NZ511466A (en) Small functional units of antibody heavy chain variable regions
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
CA2212702A1 (en) Mucosal vascular addressins and uses thereof
CN106977598A (zh) 糖基化重复基序分子缀合物
DE69321580T2 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
Kumar et al. Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines.
JP6598344B2 (ja) 環状ペプチドをタンパク質構造に提示させる超汎用法
HU9300900D0 (en) Human gamma-interferon antagonists
Wienands et al. The B cell antigen receptor of class IgD can be expressed on the cell surface in two different forms
KR930701620A (ko) 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
Peters et al. Binding and internalization of biotinylated interleukin-2 in human lymphocytes
JPS6468661A (en) Immunological method for determining isolated substance having hapten nature
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
Wilkinson et al. Binding of antibodies raised against tumour necrosis factor alpha (TNFα) to blood vessels and macrophages in inflamed synovial tissue
Storch et al. A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometric assay
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
Vedeler et al. Solubilization of human peripheral nerve Fcγ receptors and purification of a functional 40 kDa receptor
Hara et al. Interleukin 5 up-regulates high-affinity interleukin 2 receptor expression by human resting peripheral T cells: a comparison with the effect of interleukin 4 on B cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee